NSABP Foundation
The legacy US surgical adjuvant trials group that proved lumpectomy equals mastectomy, tamoxifen prevents breast cancer and trastuzumab cures more HER2-positive disease.
Founded in 1958 and led for decades by Bernard Fisher, the NSABP ran the trials that rewrote breast cancer surgery and adjuvant therapy: B-04 and B-06 showed breast conservation equals mastectomy, B-14 and B-20 provided the samples that validated the Oncotype DX recurrence score, P-1 showed tamoxifen prevents breast cancer, B-31 (with NCCTG N9831) established adjuvant trastuzumab, and B-32 validated sentinel node biopsy. It also ran colorectal adjuvant trials (C-series). NSABP merged with RTOG and GOG into NRG Oncology in 2014; the NSABP Foundation continues industry-partnered trials such as KATHERINE (with the German Breast Group) and the neoadjuvant B-series.
- B-04 / B-06 (breast conservation)
- P-1 (tamoxifen prevention)
- B-31 (adjuvant trastuzumab)
- KATHERINE (with GBG)
- Oncotype DX validation (B-14, B-20)
Pages like this
not linked directly; found by shared links- PersonGunter von Minckwitz
Shares KATHERINE, German Breast Group (GBG), Trastuzumab emtansine, HER2-positive breast cancer.
- PersonCharles E. Geyer Jr.
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), KATHERINE, Trastuzumab emtansine, NRG Oncology.
- InstitutionAustrian Breast & Colorectal Cancer Study Group
Shares German Breast Group (GBG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonBernard Fisher
Shares NRG Oncology, Chemoprevention & risk-reducing surgery, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PersonMartine Piccart
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), Trastuzumab, HER2-positive breast cancer.
- PersonBarbara Bradfield
Shares HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab), Trastuzumab, HER2-positive breast cancer.
- InstitutionInstituto Alexander Fleming
Shares Trastuzumab, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- InstitutionGeorgetown Lombardi Comprehensive Cancer Center
Shares Endocrine therapy (SERMs, AIs, SERDs), Trastuzumab, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.